Institutional Infrastructure
for Venture Capital
Syndication & Co-Investment

US-based healthtech startup Courier Health has raised $50 million in a Series B funding round to expand its AI-powered patient experience platform built for the biopharmaceutical industry, as life sciences companies increasingly prioritize personalized engagement and treatment access support.The round was led by Oak HC/FT, with participation from existing investors and strategic backers, signaling strong confidence in digital infrastructure that helps pharma brands improve patient journeys across complex therapies and specialty care.Founded to modernize how biopharma companies connect with patients, Courier Health provides CRM and patient relationship management software tailored for life sciences organizations. Its platform enables manufacturers to manage onboarding, adherence, support programs, and ongoing communication in a more consumer-grade, data-driven manner.Traditional patient support programs in pharma often rely on fragmented vendors, outdated systems, and disconnected data sources. Courier Health aims to replace this model with a unified platform that helps brands streamline enrollment, improve therapy starts, reduce abandonment, and strengthen long-term patient outcomes.A major focus of the new funding will be expansion of the company’s AI capabilities. These tools are expected to automate workflows, personalize outreach, surface insights for care teams, and improve efficiency across support operations reflecting the broader rise of AI in healthcare engagement.The company plans to use the new capital to scale product development, grow commercial teams, and deepen partnerships with biopharma clients launching specialty medicines in areas such as oncology, rare disease, and immunology.As drug innovation advances rapidly, the patient experience layer has become increasingly important. Courier Health is positioning itself as a next-generation infrastructure provider at the intersection of healthcare, software, and AI helping biopharma companies translate scientific breakthroughs into better real-world access and outcomes

San Jose-based semiconductor infrastructure startup Point2 Technology has closed an extension of its Series B funding round, bringing total Series B capital to $76 million as investor interest intensifies around next-generation AI data center hardware. The latest raise underscores the growing importance of high-speed interconnect solutions as AI workloads scale globally.The extension round was led by Maverick Silicon, with participation from NVentures and UMC Capital. Their backing highlights strong strategic confidence from investors tied closely to semiconductor and advanced computing ecosystems.Founded to solve data transfer bottlenecks inside hyperscale computing systems, Point2 develops RF-based interconnect technology designed to outperform traditional copper and optical connectivity solutions. As AI clusters become larger and more power-intensive, moving data efficiently between chips, racks, and accelerators has become a critical infrastructure challenge.The company’s flagship e-Tube platform uses RF signaling over plastic waveguides to deliver higher bandwidth density, lower latency, improved reach, and better power efficiency. This enables faster accelerator-to-accelerator communication essential for training and inference workloads powering generative AI systems.Point2 is also developing multiple deployment formats including Active RF Cables, near-package modules, and co-packaged solutions, allowing the technology to integrate across future rack-scale compute architectures. These innovations aim to reduce complexity and cost compared with conventional optical alternatives.The new capital will be used to accelerate commercialization, scale engineering teams, and support broader ecosystem deployment as cloud providers and chipmakers seek more efficient infrastructure for AI expansion.As global demand for AI compute surges, Point2 is positioning itself as a critical enabler of the next wave of data center innovation where connectivity performance may matter as much as raw processing power.

Boston-based healthcare technology startup AcuityMD has raised $80 million in a Series C funding round at a $955 million valuation, placing the company on the verge of unicorn status as investor interest surges in AI-powered healthcare commercial intelligence platforms.The round was led by StepStone Group, with participation from Benchmark, Redpoint Ventures, ICONIQ, and Atreides Management. The new financing brings AcuityMD’s total capital raised to more than $160 million, underscoring strong confidence in the company’s rapid growth trajectory.Founded in Boston, AcuityMD provides an AI platform built for the MedTech industry, helping medical device companies identify demand signals, uncover commercial opportunities, optimize territories, and accelerate adoption of medical technologies. The platform is increasingly used as healthcare sales organizations modernize with data-driven tools.The company says it is trusted by more than 400 MedTech companies, including eight of the top ten industry leaders. Its software combines healthcare market data, provider insights, and AI-powered workflows to help commercial teams improve targeting and sales execution.A key focus of the new funding will be expansion of AcuityAI, the company’s agentic AI product designed to answer complex business questions, automate planning, and generate actionable market strategies for MedTech sales teams. This signals a broader move toward AI copilots in enterprise healthcare operations.Beyond sales enablement, AcuityMD also plans to expand its platform across the full product lifecycle, supporting research, development, launch strategy, and commercialization of next-generation medical devices.As healthcare and enterprise AI continue to converge, AcuityMD is emerging as one of the most valuable vertical SaaS players in MedTech positioned at the intersection of healthcare innovation, data intelligence, and commercial automation.

India-based hospitality startup The Hosteller has raised ₹150 crore (approximately $18 million) in a Series B funding round, marking one of the largest institutional fundraises in India’s hostel and backpacker accommodation segment. The investment highlights growing confidence in India’s fast-expanding experience-led travel market.The round was led by PROMAFT Partners and V3 Ventures, with participation from ITI Growth Opportunities Fund, Merisis Wealth Trust, and prominent family offices. The financing reflects strong investor belief in branded budget hospitality models focused on young domestic travellers.Founded in 2014, The Hosteller has built one of India’s largest hostel networks, operating more than 75 properties across 13 states. The company says it has already hosted over 20 lakh travellers, benefiting from rising demand for affordable, community-driven stays among Gen Z and millennial travellers.Over the past 12 months, the startup added more than 30 new properties and increased capacity by nearly 70%, demonstrating rapid expansion momentum as domestic tourism rebounds strongly.The newly raised capital will be used to expand into key travel destinations, strengthen operational efficiency, and scale brand presence nationwide. The company is targeting 25,000 beds over the next 36 months, significantly expanding its national footprint.The Hosteller also plans to launch a travel super app integrating accommodation, food & beverage, mobility, and curated experiences into a single platform positioning itself beyond hostel stays into a broader youth travel ecosystem.As Indian travellers increasingly prioritize experiences over traditional hotel formats, The Hosteller is emerging as a category leader in organized budget travel and experiential hospitality.

US-based biotech startup Ray Therapeutics has raised an upsized and oversubscribed $125 million Series B funding round to accelerate development of its optogenetic gene therapies for blinding retinal diseases, reinforcing investor confidence in next-generation vision restoration technologies.The financing follows the company’s previously oversubscribed $100 million Series A and marks a major milestone as Ray Therapeutics moves toward later-stage clinical development of its lead ophthalmology programs.Founded in San Diego, Ray Therapeutics is developing optogenetic therapies that aim to restore vision by making surviving retinal cells responsive to light. Unlike mutation-specific treatments, the company’s platform is designed to work across multiple retinal degenerative diseases where photoreceptor cells have been lost.Its lead candidate targets conditions such as retinitis pigmentosa, while the broader pipeline includes programs for inherited retinal dystrophies and macular degeneration. These diseases currently have limited treatment options and affect millions globally, creating strong demand for durable restorative therapies.Optogenetics is considered one of the most promising frontiers in ophthalmology because it combines gene therapy with engineered light-sensitive proteins to potentially restore functional sight. Ray Therapeutics has focused on developing therapies that may not require external light-enhancing devices, improving real-world usability for patients.The newly raised capital is expected to support clinical trials, manufacturing scale-up, regulatory progress, and continued expansion of the company’s research platform. As gene therapy innovation accelerates, Ray Therapeutics is positioning itself as a leader in restorative vision medicine.With strong investor backing and growing momentum in precision ophthalmology, the company is now entering a critical phase where breakthrough science could translate into life-changing patient outcomes.

China-based robotics startup X Square Robot has raised RMB 2 billion (approximately $275 million) in a Series B funding round, marking one of the largest robotics financings of the year and highlighting rising investor confidence in next-generation intelligent automation.The fresh capital is expected to support large-scale commercialization, advanced robotics R&D, and expansion of manufacturing capacity as demand grows for AI-powered industrial robots across logistics, warehousing, manufacturing, and smart factory environments.Founded to modernize industrial operations through robotics and autonomous systems, X Square Robot develops intelligent robotic platforms designed to improve productivity, reduce labor dependency, and optimize complex workflows. The company is focused on integrating AI perception, machine learning, motion control, and real-time decision systems into scalable robotic solutions.China continues to be one of the world’s largest and fastest-growing robotics markets, driven by rising labor costs, aging demographics, supply chain modernization, and strong government support for advanced manufacturing. In this environment, companies like X Square Robot are emerging as strategic enablers of industrial transformation.The new funding round is expected to strengthen the company’s position in sectors such as smart logistics, precision manufacturing, and autonomous warehouse operations segments experiencing rapid demand from enterprises seeking higher efficiency and resilient supply chains.Beyond domestic opportunities, the raise may also help X Square Robot expand internationally as Chinese robotics firms increasingly compete in global markets with cost-efficient and technologically advanced solutions.As AI and robotics converge to reshape factories and infrastructure worldwide, X Square Robot is positioning itself as a major player in the future of intelligent automation and industrial productivity.